GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MEMP1972A in Patients With Allergic Rhinitis
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01160861
A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
- Conditions
- Basal Cell Carcinoma
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01160250
A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01139723
A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy
Phase 4
Completed
- Conditions
- Allergic Asthma
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT01125748
A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01122875
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT01120561
- Locations
- 🇺🇸
Investigational Site, Seattle, Washington, United States
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT01106599
A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
- First Posted Date
- 2010-03-23
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT01090960
A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)
- First Posted Date
- 2010-03-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT01087151
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT01075464
© Copyright 2025. All Rights Reserved by MedPath